Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Test entities : Guardant health, inc. save search
FDA Advisory Panel Review of Guardant Health’s Shield™ Blood Test to Screen for Colorectal Cancer to Be Held on May 23
Published: 2024-04-22 (Crawled : 14:00) - biospace.com/
GH | News 4 | $18.1 4.38% 4.2% 1.8M
|
Health Services
|
| O: 4.42%
H: 5.36%
C: 4.83%
fda test review cancer blood for
Guardant Health ECLIPSE Study Data Demonstrating Efficacy of Shield Blood-based Test for Colorectal Cancer Screening to be Published in The New England Journal of Medicine
Published: 2024-03-13 (Crawled : 23:00) - biospace.com/
GH | News 4 | $18.1 4.38% 4.2% 1.8M
|
Health Services
|
| O: -0.75%
H: 4.38%
C: 2.7%
test health cancer study
Guardant Health launches Shield blood-based screening test for colorectal cancer in South Korea
Published: 2023-11-13 (Crawled : 00:00) - prnewswire.com
GH | News 4 | $18.1 4.38% 4.2% 1.8M
|
Health Services
|
| O: 2.73%
H: 2.12%
C: 2.07%
test health cancer
Guardant Health Provides Update on COBRA Study, Restates Confidence in MRD Test
Published: 2023-09-01 (Crawled : 22:00) - biospace.com/
GH | News 4 | $18.1 4.38% 4.2% 1.8M
|
Health Services
|
| O: 1.15%
H: 2.4%
C: -11.43%
test health update
Guardant Health announces reimbursement approval of Guardant360® CDx liquid biopsy test in Japan
Published: 2023-07-05 (Crawled : 13:00) - biospace.com/
GH | News 4 | $18.1 4.38% 4.2% 1.8M
|
Health Services
|
| O: -0.08%
H: 3.58%
C: 2.95%
guardant360 test japan health approval
Guardant Health Receives Regulatory Approval from Singapore's Health Sciences Authority for Guardant360® CDx blood test for patients with advanced solid cancers
Published: 2023-05-30 (Crawled : 01:00) - prnewswire.com
GH | News 4 | $18.1 4.38% 4.2% 1.8M
|
Health Services
|
| O: 2.24%
H: 3.41%
C: -0.17%
guardant360 test health approval blood sciences
Guardant Health presents additional information from ECLIPSE study at 2023 Digestive Disease Week on the performance of Shield™ blood test
Published: 2023-05-09 (Crawled : 20:00) - biospace.com/
GH | News 4 | $18.1 4.38% 4.2% 1.8M
|
Health Services
|
| O: -1.1%
H: 4.06%
C: 3.09%
disease test health blood week study
Guardant Health submits premarket approval application to the U.S. Food and Drug Administration for Shield™ blood test
Published: 2023-03-10 (Crawled : 17:00) - biospace.com/
GH | News 4 | $18.1 4.38% 4.2% 1.8M
|
Health Services
|
| O: -0.59%
H: 0.3%
C: -6.61%
blood drug test health application approval food
Guardant Health Initiates New Study to Examine the Impact of Shield™ Blood Test to Increase Screening Compliance for Colorectal Cancer
Published: 2023-02-15 (Crawled : 16:00) - biospace.com/
GH | News 4 | $18.1 4.38% 4.2% 1.8M
|
Health Services
|
| O: 0.29%
H: 3.64%
C: 3.46%
blood test impact health cancer study
Guardant Health receives coverage from UnitedHealthcare for Guardant360® CDx blood test as companion diagnostic in advanced lung and breast cancer
Published: 2023-02-08 (Crawled : 15:00) - biospace.com/
GH | News 4 | $18.1 4.38% 4.2% 1.8M
|
Health Services
|
| O: -0.11%
H: 9.85%
C: 4.35%
guardant360 blood lung test diagnostic breast health cancer
Guardant Health and The Royal Marsden NHS Foundation Trust partner on highly anticipated TRACC Part C trial to use Guardant Reveal™ blood test to help guide treatment decisions in colorectal cancer
Published: 2023-01-19 (Crawled : 14:20) - biospace.com/
GH | News 4 | $18.1 4.38% 4.2% 1.8M
|
Health Services
|
| O: -1.0%
H: 0.93%
C: -0.03%
treatment blood test health trial trust cancer
Guardant Health Expands Use of Guardant Reveal™ Liquid Biopsy Test for Residual Disease Detection and Recurrence Monitoring to Include Early-Stage Breast and Lung Cancers
Published: 2022-08-15 (Crawled : 13:00) - biospace.com/
GH | News 4 | $18.1 4.38% 4.2% 1.8M
|
Health Services
|
| O: -0.04%
H: 4.97%
C: 1.62%
lung disease test health
First Guardant Health Liquid Biopsy Testing Service in Europe Now Operational at Vall d’Hebron Institute of Oncology
Published: 2022-05-25 (Crawled : 11:00) - biospace.com/
GH | News 4 | $18.1 4.38% 4.2% 1.8M
|
Health Services
|
| O: -0.12%
H: 1.65%
C: -1.41%
europe service health test
Guardant Health Announces Shield™ Blood Test Available in US to Detect Early Signs of Colorectal Cancer in Average-Risk Adults
Published: 2022-05-02 (Crawled : 13:00) - biospace.com/
GH | News 4 | $18.1 4.38% 4.2% 1.8M
|
Health Services
|
| O: -4.23%
H: 3.23%
C: 0.37%
blood test health cancer
Guardant Health to Present New Data from its Broad Portfolio of Blood Tests at the American Association for Cancer Research Annual Meeting
Published: 2022-03-09 (Crawled : 22:00) - biospace.com/
GH | News 4 | $18.1 4.38% 4.2% 1.8M
|
Health Services
|
| O: 2.71%
H: 5.58%
C: 4.56%
america health blood research test cancer
Guardant Health Receives Medicare Coverage for Guardant360 TissueNext™ Test
Published: 2022-03-08 (Crawled : 17:00) - guardanthealth.com
GH | News 4 | $18.1 4.38% 4.2% 1.8M
|
Health Services
|
| O: -0.47%
H: 11.04%
C: 5.07%
health test
Guardant Health to Present Data Highlighting the Clinical Utility of Its Liquid Biopsy Tests in Gastrointestinal Cancers at ASCO GI Cancers Symposium
Published: 2022-01-19 (Crawled : 15:00) - biospace.com/
GH | News 4 | $18.1 4.38% 4.2% 1.8M
|
Health Services
|
| O: -3.27%
H: 3.07%
C: -1.0%
health symposium gastrointestinal asco test cancer
Guardant Health Enrolls First Patient in SHIELD LUNG Study to Evaluate Accuracy of Its Blood Test to Detect Lung Cancer in High-Risk Adults
Published: 2022-01-18 (Crawled : 15:30) - biospace.com/
GH | News 4 | $18.1 4.38% 4.2% 1.8M
|
Health Services
|
| O: -3.08%
H: 0.0%
C: 0.0%
health blood risk lung cancer test cancer enroll
Guardant Health Reaches Target Enrollment of 12,750 Patients in ECLIPSE Pivotal Study for its LUNAR™-2 Blood Test to Detect Colorectal Cancer
Published: 2021-12-17 (Crawled : 13:30) - biospace.com/
GH | News 4 | $18.1 4.38% 4.2% 1.8M
|
Health Services
|
| O: -0.78%
H: 0.0%
C: 0.0%
health blood test cancer colorectal cancer enroll
Study Shows Guardant360® Liquid Biopsy Test Helps Guide Treatment for Patients with HER2-Driven Metastatic Colorectal Cancer
Published: 2021-11-11 (Crawled : 23:00) - biospace.com/
GH | News 4 | $18.1 4.38% 4.2% 1.8M
|
Health Services
|
| O: 0.18%
H: 1.32%
C: 1.27%
treatment test cancer colorectal cancer her2+ her2- her2
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
WHLM | $6.25 35.87% 28.46% 700K
|
Commercial Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
Your saved searches
Save your searches and get alerts when important news are released.